Metformin as a Chemopreventive Agent for Colorectal Adenoma Recurrence: Evidence from Randomized Controlled Trials
Abstract
BACKGROUND: Colorectal adenomas are well-established precursors of colorectal cancer (CRC), with recurrence rates of up to 50% following polypectomy. Safe and effective chemopreventive strategies are needed. Metformin, a widely used antidiabetic agent, has demonstrated potential anticancer effects, but its role in adenoma prevention among non-diabetic individuals remains uncertain. OBJECTIVE: To evaluate the efficacy and safety of metformin in preventing metachronous colorectal adenoma recurrence in non-diabetic adults following complete endoscopic polypectomy. METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted in accordance with PRISMA guidelines. Databases including PubMed, Embase, Cochrane CENTRAL, Web of Science, and Scopus were searched from inception to December 2025. Eligible studies included RCTs comparing metformin with placebo or no intervention in non-diabetic adults with prior adenoma resection, reporting recurrence at ≥12 months. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. RESULTS: Two RCTs comprising 405 participants were included. Metformin significantly reduced the risk of adenoma recurrence at 1 year compared with control (RR 0.61, 95% CI 0.48-0.78; I² = 0%). This corresponds to an approximate 39% relative risk reduction. The effect was consistent across different dosing regimens (250-1000 mg/day). Both trials demonstrated low risk of bias and reported good…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 405 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.